On August 27, Genscript Bio (01548.HK) announced that on August 27, 2024, the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for cilta-cel submitted by its non-wholly owned subsidiary, Legend Biotech Co., Ltd. The product is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who meet the specified criteria.
金斯瑞生物科技(01548.HK)：传奇生物提交的西达基奥仑赛(cilta-cel)新药上市申请获批准
Genscript Bio (01548.HK): The new drug application for Sida Jiaolun Sai (cilta-cel) submitted by Legend Biotech has been approved.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.